Browsing Tag
belantamab mafodotin
3 posts
FDA approves GSK’s Blenrep for myeloma—what sets it apart from CAR-T options?
GSK’s Blenrep approved by the FDA for relapsed multiple myeloma after Phase III trial success. Learn what this means for U.S. patients and global expansion.
GSK’s Blenrep shows significant efficacy in DREAMM-7 trial in multiple myeloma
GSK plc has unveiled promising results from the DREAMM-7 phase III trial, which highlights a notable advancement in…
GSK’s DREAMM-7 trial shows promising results for Blenrep in multiple myeloma
GSK plc has unveiled positive outcomes from the DREAMM-7 head-to-head phase III trial, evaluating Blenrep (belantamab mafodotin) as…